Literature DB >> 22054886

Evaluation and treatment of high-risk patients with early-stage lung cancer.

Hiren J Mehta1, Christopher Ross, Gerard A Silvestri, Roy H Decker.   

Abstract

Standard therapy for early-stage non-small cell lung cancer is lobectomy for patients who are able to tolerate such surgery. However, the risk of postoperative morbidity is not trivial, with a 30% to 40% incidence of postoperative complications and a 1% to 5% incidence of operative mortality. Some patients, though technically resectable, refuse surgery or are considered medically inoperable because of insufficient respiratory reserve, cardiovascular disease, or general frailty. This group is considered either "high risk" or "medically inoperable." Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22054886     DOI: 10.1016/j.ccm.2011.08.011

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  4 in total

Review 1.  The Latest on Lung Ablation.

Authors:  Peyton Cramer; Bradley B Pua
Journal:  Semin Intervent Radiol       Date:  2022-08-31       Impact factor: 1.780

Review 2.  Lung cancer in elderly patients.

Authors:  Federico Venuta; Daniele Diso; Ilaria Onorati; Marco Anile; Sara Mantovani; Erino A Rendina
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

3.  Use of new treatment modalities for non-small cell lung cancer care in the Medicare population.

Authors:  Michael T Vest; Jeph Herrin; Pamela R Soulos; Roy H Decker; Lynn Tanoue; Gaetane Michaud; Anthony W Kim; Frank Detterbeck; Daniel Morgensztern; Cary P Gross
Journal:  Chest       Date:  2013-02-01       Impact factor: 9.410

Review 4.  Local Control After Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer.

Authors:  Percy Lee; Billy W Loo; Tithi Biswas; George X Ding; Issam M El Naqa; Andrew Jackson; Feng-Ming Kong; Tamara LaCouture; Moyed Miften; Timothy Solberg; Wolfgang A Tome; An Tai; Ellen Yorke; X Allen Li
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-04-05       Impact factor: 8.013

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.